AUTHORS
Katarzyna Anna Szoltysek, PhD, Edward Law, PhD2, Helen Blair, PhD3, Lynsey McKenzie, PhD4, Mankaran Singh, PhD5, Elda Latif, PhD6, Katherine Dormon, PhD7, Hesta McNeill8, Alex Elder, PhD9, Melanie Beckett, PhD10, Ryan Nelson11, Matthew Bashton, PhD12, Sirintra Nakjang, PhD13, Minoo Ashtiani14, Shilpa Narina15, Wenjie Qi16, Wojciech Rosikiewicz, PhD17, Deepali Pal, PhD18, Simon Bomken, MD/PhD19, John Lunec, PhD20, Christine Harrison, PhD, FMedSci21, Charles G. Mullighan, MBBS (Hons), MSc, MD22, Josef Vormoor, MD23, Olaf Heidenreich, PhD24
AFFILIATIONS
1 Newcastle University, Newcastle upon Tyne, United Kingdom, St. Jude Children's Research Hospital, Memphis, Tennessee, United States
2 Newcastle University, Newcastle upon Tyne, United Kingdom
3 Newcastle University, Newcastle upon Tyne, United Kingdom
4 Newcastle University, Newcastle upon Tyne, United Kingdom
5 Newcastle University, Newcastle upon Tyne, United Kingdom
6 Newcastle University, Newcastle upon Tyne, United Kingdom
7 Newcastle University, Newcastle upon Tyne, United Kingdom
8 Newcastle University, Newcastle upon Tyne, United Kingdom
9 Newcastle University, Newcastle upon Tyne, United Kingdom
10 Newcastle University, Newcastle upon Tyne, United Kingdom
11 Newcastle University, Newcastle upon Tyne, United Kingdom
12 Newcastle University, Newcastle upon Tyne, United Kingdom, Northumbria University, Newcastle upon Tyne, United Kingdom
13 Newcastle University, Newcastle upon Tyne, United Kingdom
14 Prinses Máxima Centrum Voor Kinderoncologie, Utrecht, Netherlands
15 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
16 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
17 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
18 Newcastle University, Newcastle upon Tyne, United Kingdom, University of Bristol, Bristol, United Kingdom
19 Newcastle University, Newcastle upon Tyne, United Kingdom
20 Newcastle University, Newcastle upon Tyne, United Kingdom
21 Newcastle University, Newcastle upon Tyne, United Kingdom
22 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
23 Newcastle University, Newcastle upon Tyne, United Kingdom, Prinses Máxima Centrum Voor Kinderoncologie, Utrecht, Netherlands
24 Newcastle University, Newcastle upon Tyne, United Kingdom, Prinses Máxima Centrum Voor Kinderoncologie, Utrecht, Netherlands
ABSTRACT
Acute lymphoblastic leukemia (ALL) is the most common type of pediatric cancer with survival rates of ~90%. Nevertheless, remaining and refractory/relapsed cases are associated with dismal outcomes and represent an unmet clinical need for continued improvement of current treatment options. Molecular heterogeneity of high-risk ALL subtypes, relatively small number of patients within each subtype and lack of experimental models representing these diseases further underscore the need to develop alternative research strategies required for this goal.
In this study, we aimed to identify therapeutically targetable vulnerabilities in patients with very high-risk ALL. To that end, we combined ex vivo co-culture and in vivo transplantation of patient-derived xenotransplant (PDX) ALL cells with CRISPR screening, next generation sequencing and multidimensional drug testing to uncover clinically actionable dependencies in PDX cells. We initially focused on patient-matched diagnostic and relapse cells representing t(17;19) TCF3::HLF ALL subtype, characterized by very low/absent overall survival. To support long-term ex vivo propagation of patient-derived cells, we employed co-culture platforms with human bone-marrow derived mesenchymal stromal cells (MSC) used as a feeder layer for leukemic blasts. We then performed genome-wide CRISPR screens comparing both ex vivo co-culture and xenograft in vivo mice models.
Notably, all screens predicted loss of glucocorticoid receptor gene expression (NR3C1) as a driver of relapse, a gene subsequently confirmed to be deleted in the patient relapse sample. Furthermore, depletion of sgRNA guides targeting TCF3 gene identified by CRISPR screens highlighted the requirement of continuous TCF3::HLF fusion oncogene expression for maintaining the leukemic phenotype. CRISPR screening and CUT&RUN further identified RUNX1 as an essential dependency in TCF3::HLF ALL, binding directly to the promoters of TCF3 driver gene itself as well as genes involved in MYC and mTOR signaling pathways. Consistent with these mechanistic findings, CRISPR screens revealed dependency on the pro-survival mTOR pathway as well as BCL2 and p53-MDM2 networks that regulate pro-apoptotic cellular signaling.
Evaluation studies of drug synergies using the same ex vivo platform identified four-drug combination - termed DIVE - targeting glucocorticoid receptor (Dexamethasone), MDM2 (Idasanutlin), BCL2 (Venetoclax) and mTOR (Everolimus), as the most promising multidrug therapy for TCF3::HLF leukemia. However, due to observed toxicity in the in vivo PDX model, we excluded Everolimus from subsequent studies. To select the lowest, most efficacious dose of each drug, we tested three-drug DIV (Dexamethasone, Idasanutlin, Venetoclax) combination ex vivo in fifteen PDX samples representing TCF3::HLF, KMT2Ar, Ph+, iAMP21, low hypodiploid and high-hyperdiploid subtypes. All samples responded strongly to DIV combination, except for TP53mut low hypodiploid sample, which showed sensitivity only towards BCL2 inhibition. This reliance on BCL2 was further functionally examined using BH3 profiling and confirmed across all tested PDX samples.
Finally, we conducted a pre-clinical in vivo study across four selected PDX samples and found that DIV combination substantially prolonged survival in every model examined. Notably, DIV achieved long-term survival in PDX models derived from lineage switching KMT2Ar and low-hypodiploid B-ALL. In contrast, TCF3::HLF samples relapsed immediately after treatment cessation indicating presence of treatment resistant or protected leukemia-repopulating cell (LRC) reservoir in our in vivo model. Leukemic cells isolated from relapsed animals showed increased resistance towards dexamethasone and idasanutlin upon ex vivo re-challenge with single agent treatment. Apart from NR3C1 deletion, genomic analyses did not identify additionally acquired mutations, whereas gene expression analyses revealed upregulation of PDK4 and FLT3. These results suggested involvement of metabolic rewiring and further pointed into PI3K/AKT/mTOR signaling in TCF3::HLF leukemia.
In summary, our work demonstrates that ex vivo co-culture platforms provide faithful and predictive approach for studies requiring direct use of patient-derived samples. We propose combined inhibition of MDM2 and BCL2 as a promising treatment option for high-risk B-ALL patients and recommend inclusion of Idasanutlin-Venetoclax combinations for further pre-clinical evaluation.
DISCLOSURES
Katarzyna Anna Szoltysek, PhD: No relevant conflicts of interest to declare.